Company: INMB
Filing Date: 2025-06-16
Form Type: S-8
Source: 0001213900-25-054427
Chunk: 3

Company: Inmune Bio, Inc.
Filing Date: 2025-06-16
Form: S-8
Chunk 3
---
 prospectus relates to the aggregate
sale of 3,065,332 shares of our common stock that may be offered and resold from time to time by the selling stockholders identified in
this reoffer prospectus for their own account. Such shares have been or may be acquired in connection with 3,065,332 awards granted under
the 2021 Plan. It is anticipated that the selling stockholders will offer shares for sale at prevailing prices on the Nasdaq Capital Market
on the date of sale. We will receive no part of the proceeds from sales made under this reoffer prospectus. The selling stockholders will
bear all sales commissions and similar expenses. Any other expenses incurred by us in connection with the registration and offering and
not borne by the selling stockholders will be borne by us.

This reoffer prospectus has been prepared for
the purposes of registering the shares under the Securities Act to allow for future sales by selling stockholders on a continuous or delayed
basis to the public without restriction.

The selling stockholders and any brokers executing
selling orders on their behalf may be deemed to be “underwriters” within the meaning of the Securities Act, in which event
commissions received by such brokers may be deemed to be underwriting commissions under the Securities Act.

Our common stock is quoted on the Nasdaq Capital
Market under the symbol “INMB.” The last reported sale price of our common stock on the Nasdaq Capital Market on June 12,
2025, was $7.92 per share.

Investing in our common stock involves a high degree of risk. See “Risk Factors” beginning on page 2 of this reoffer prospectus.

Neither the Securities and Exchange Commission (the “SEC”) nor any state securities commission has approved or disapproved of these securities or determined if this reoffer prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this reoffer prospectus is June
13, 2025.

TABLE OF CONTENTS</div>

|                                                                                     | Page |
| Cautionary Note Regarding Forward Looking Statements                                |   ii |
| Prospectus Summary                                                                  |    1 |
| Risk Factors                                                                        |    2 |
| Determination of Offering Price                                                     |    3 |
| Use of Proceeds                                                                     |    3 |
| Selling Stockholders                                                                |    3 |
| Plan of Distribution                                                                |    5 |
| Legal Matters                                                                       |    7 |
| Experts                                                                             |